A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This study is testing a new drug called STM-416 in patients with non-invasive bladder cancer that keeps coming back after standard treatment, given at the time of surgical tumor removal (TURBT). **You may be eligible if...** - You are 18 or older - You have high-grade non-muscle-invasive bladder cancer (cancer that has not grown into the bladder wall muscle) that has recurred after prior treatments - You are considered at high risk for the cancer coming back again - You are scheduled for a TURBT (bladder tumor removal via scope) without additional bladder-instilled chemotherapy - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have ever had cancer that grew into the bladder muscle wall, or a cancer type called carcinoma in situ (CIS) of the bladder - You are taking other experimental drugs - You are allergic to similar compounds in STM-416 - You have uncontrolled heart disease, active infection, or significant psychiatric illness - You are a woman of childbearing potential (in the earlier phases of this study) Talk to your doctor to see if this trial is right for you.